239 related articles for article (PubMed ID: 15377472)
21. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).
Uyl-de Groot CA; Hagenbeek A; Verdonck LF; Löwenberg B; Rutten FF
Bone Marrow Transplant; 1995 Sep; 16(3):463-70. PubMed ID: 8535321
[TBL] [Abstract][Full Text] [Related]
23. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
24. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
25. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy.
Mead GM; Bleehen NM; Gregor A; Bullimore J; Shirley D; Rampling RP; Trevor J; Glaser MG; Lantos P; Ironside JW; Moss TH; Brada M; Whaley JB; Stenning SP
Cancer; 2000 Sep; 89(6):1359-70. PubMed ID: 11002232
[TBL] [Abstract][Full Text] [Related]
26. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
27. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
28. [Dose reduction is not recommended for elderly patients undergoing chemotherapy for non-Hodgkin lymphoma].
Sonneveld P; Huijgens PC; Hagenbeek A
Ned Tijdschr Geneeskd; 1999 Feb; 143(8):418-9. PubMed ID: 10221113
[TBL] [Abstract][Full Text] [Related]
29. Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma.
Burton C; Smith P; Vaughan-Hudson G; Qian W; Hoskin P; Cunningham D; Hancock B; Linch D
Br J Haematol; 2005 Aug; 130(4):536-41. PubMed ID: 16098067
[TBL] [Abstract][Full Text] [Related]
30. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.
Pui CH; Boyett JM; Hughes WT; Rivera GK; Hancock ML; Sandlund JT; Synold T; Relling MV; Ribeiro RC; Crist WM; Evans WE
N Engl J Med; 1997 Jun; 336(25):1781-7. PubMed ID: 9187068
[TBL] [Abstract][Full Text] [Related]
31. Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
Costello RT; Zerazhi H; Charbonnier A; de Colella JM; Alzieu C; Poizot-Martin I; Cohen R; Bardou VJ; Xerri L; Olive D; Nezri M; Lepeu G; Gastaut JA
Cancer; 2004 Feb; 100(4):667-76. PubMed ID: 14770420
[TBL] [Abstract][Full Text] [Related]
32. Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage non-Hodgkin's lymphoma patients.
Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Shono Y; Morioka M; Kawamura T; Masauzi N; Kakinoki Y; Kobayashi H; Kunieda Y; Kasai M; Kurosawa M; Asaka M; Imamura M
Eur J Haematol; 2006 Nov; 77(5):403-9. PubMed ID: 16930137
[TBL] [Abstract][Full Text] [Related]
33. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
34. A long-term follow-up study of prospective 80%-dose CHOP followed by involved-field radiotherapy in elderly lymphoma patients.
Shikama N; Oguchi M; Isobe K; Nakamura K; Tamaki Y; Hasegawa M; Kodaira T; Sasaki S; Kagami Y;
Jpn J Clin Oncol; 2011 Jun; 41(6):764-9. PubMed ID: 21459892
[TBL] [Abstract][Full Text] [Related]
35. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
[TBL] [Abstract][Full Text] [Related]
37. Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma.
Lokich JJ
Am J Clin Oncol; 2006 Aug; 29(4):361-3. PubMed ID: 16891862
[TBL] [Abstract][Full Text] [Related]
38. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
39. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
Tsukasaki K; Utsunomiya A; Fukuda H; Shibata T; Fukushima T; Takatsuka Y; Ikeda S; Masuda M; Nagoshi H; Ueda R; Tamura K; Sano M; Momita S; Yamaguchi K; Kawano F; Hanada S; Tobinai K; Shimoyama M; Hotta T; Tomonaga M;
J Clin Oncol; 2007 Dec; 25(34):5458-64. PubMed ID: 17968021
[TBL] [Abstract][Full Text] [Related]
40. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
